

Hull and East Riding Prescribing Committee Minutes – Confirmed

| | |
|------------------------------|--|
| Date / Time | Wednesday 26 TH July 2017 |
| Venue | The Board Room, ,Health House, Willerby |
| Chair | Dr S Raise, GP Prescribing Lead, ER |
| Notes / Action Points | Mrs S Greene, Senior Pharmacy Technician – Formulary/Interface, HEY. |
| Quorate: Yes / No | Yes |

Mr Kevin McCorry, Senior Pharmacist, ERY, NECS
Prof A Morice, Professor of Respiratory Medicine
Mr D Corral, Chief Pharmacist, Clinical Director Therapy & Therapeutics, HEY
Dr Krishna Kasaraneni, Humberside LMC Medical Director
Mr S Gaines, Senior Principal Pharmacist, HEY
Mrs Jackie Stark, Principal Pharmacist Humber
Jane Morgan, Acting Senior Principal Pharmacist Interface
Ms Elizabeth Lyle, Senior Pharmacist – Hull, NECS
Mrs Ana Megias-bas Senior Pharmacist, HEY
Mr Graham Hill, Senior Pharmacist CHCP

| | |
|------------------|--|
| Apologies | Phil Davis, Head Of Primary Care, Hull, CCG Tim Allison Dr K Raghunath, GP Prescribing Lead, Hull CCG Judith Williamson (Spire) Janet Clarke Chief Officer Local Pharmaceutical Committee ERHLPC |
|------------------|--|

| Agenda No | Item | Discussion | Decision Made | Action | Lead | Due Date/Date complete |
|------------|---------------------------------|--|-------------------------------|------------------|------|------------------------|
| 2017.07.01 | Apologies | As above. | | | | |
| 2017.07.02 | Declarations of Interest | None. | | | | |
| 2017.07.03 | Minutes of the previous meeting | <p>Some changes were made to minutes.</p> <p>Prescribing Guidelines, shared care frameworks for Approval Guanfacine- Feedback needed from Public Health England re incidents JM to contact, was added.</p> <p>Guideline for Prescribing Medications Framework for The Treatment and Management of Dementia – JS to send formal document to LMG and feedback to HERPC- was removed from the Decision Made column.</p> <p>Fluticasone Furoate and Vilanterol (Relvar Ellipta) For Patients on DOT therapy only Patients would be on the SMART regime was removed.</p> | | Action Completed | | 7/17 |
| 2017.07.04 | Action Tracker | <p>Paediatric Growth Hormone SCF JM had met with consultants and nurses. There seems to be some difficulties in identifying patient numbers, as the original data included adults, and the patients obtain their prescriptions from Homecare, which makes it even more difficult to obtain data.</p> <p>Decision making process –KM and SR has discussed, and realised that there is a pathway to go through before anything can be confirmed, and it would not be one person's</p> | More Data is needed - Ongoing | Action Complete | JM | 9/17 7/17 |

| | | | | | |
|--|---|--|---|-------------------------------|---|
| | <p>responsibility to make decisions, therefore it was felt that this should now be removed from the tracker.</p> <p>Shared Care Framework Acetylcholinesterase Inhibitors in Dementia – LL informed the committee that Hull are piloting a scheme for the next four months. This involves five GP practices. One practice will get all referrals and they will use the current SCF with the heading in bold red letters saying ‘Patient Part Of A Pilot’ The CCG is funding the scheme.</p> <p>.</p> <p>Guanfacine shared care framework- JM had contacted Public Health and fed back there had been no data on SCD. Coroners mortality data has indicated that there were 5 patients per 100,000, these patients were under the age of 35 years. Good screening of patients was recommended as follows 1) History of patient 2) Family history of patient and 3) Physical examination. The paediatric cardiology consultant had not yet replied.</p> <p>Rhinitis Guideline Amendments needed (dexamethasone drops for fluticasone) allergy team at HEY to be contacted for feedback. Feedback received from Immunology approved.</p> <p>Guideline on Prescribing of Gonadorelin (GnRH) Analogues and Progesterone Receptor Modulators in treatment of Endometriosis, Uterine Fibroids (including pre-op use) or prior to Endometrial Ablation Currently two guidelines on website ‘old’ one to be removed. New amendments done by consultant to be reviewed</p> <p>Strong Opioid Comparison Guidelines – EB has now received feedback.</p> <p>Bisphosphonates as Supportive Therapy for Breast</p> | <p>Wait for the outcome of the scheme before updating the SCF.</p> <p>The committee felt that an answer was needed from the paediatric Cardiologist, as to whether an ECG was needed.</p> <p>.</p> <p>To go to MMIG August, then HERPC in September</p> <p>Prof Lind did not</p> | <p>LL to feedback results when completed.</p> <p>JM to feedback at next HERPC</p> <p>Action Complete</p> <p>Action Complete</p> <p>Action Complete</p> <p>Ongoing</p> | <p>LL</p> <p>JM</p> <p>JM</p> | <p>9/17</p> <p>9/17</p> <p>7/17</p> <p>7/17</p> <p>7/17</p> <p>9/17</p> |
|--|---|--|---|-------------------------------|---|

| | | | | | | |
|------------|----------------------|---|--|--|---------------------|-------------------------------------|
| | | <p>Cancer Deferred- . Prof Lind to prepare paper</p> <p>Diabetes Formulary GLP-1 Inhibitors – Waiting for feedback for Endocrinology.</p> <p>Shared Care Issues Tamoxifen GP’s are using SCF as a referral document.</p> <p>Guideline on Prescribing of Gonadrenalin Analogues and Gonadotrophin Releasing Hormone Antagonists in the Treatment of Prostate Cancer- A Degarelix SCF has been written.</p> | <p>attend, deferred to September</p> <p>Awaiting feedback.</p> <p>Awaiting feedback from Mr Simms</p> | <p>SG to add to Agenda for next HERPC</p> <p>Action Complete</p> <p>JM to feedback at next HERPC</p> | <p>SG</p> | <p>9/17</p> <p>7/17</p> <p>9/17</p> |
| 2017.07.05 | Traffic Light Status | <ul style="list-style-type: none"> HEY D&T- Levofloxacin Desmopressin Acetate Fiasp = Fast-Acting Insulin Aspart Palbociclib Capsules Otenisan Wash Lotion Brivaracetam/Briviact Tablets/Solution Glecaprevir/Pibrentasvir Tablets Relvar HFT DTC – None CHCP - Cilique and Invicorp | <p>Red Blue Green Red Green Initially Red, Dr Ming will review after 1 year. Red Change from red to blue</p> <p>Blue</p> | <p>Update Formulary</p> <p>Update Formulary</p> | <p>SG</p> <p>SG</p> | <p>9/17</p> <p>9/17</p> |

| | | | | | |
|------------|---|--|--|------------------------------|------|
| 2017.07.06 | Feedback From Commissioning Groups | KM feedback that there are consultations around Lidocaine Patches | To be discussed at MMIG and next HERPC | SG to agenda | 9/17 |
| | | Dr Krishna Kasaraneni -there will be four documents, that have been approved, and he will bring to next HERPC. | To go on tracker for next HERPC | SG to add to tracker | 9/17 |
| | | NHSE have sent a letter to all GP's stating that Pregabalin is now a category M and there will be 96% reduction in price. | Monitoring of stock levels to be done | Noted | 7/17 |
| | | The Erectile Dysfunction Guideline has been updated. | GH to send to SG/JM | SG to update website | 9/17 |
| 2017.07.07 | DMARD Prescribing Shared Care Agreement | At Januarys HERPC meeting DMARD's and prescribing were discussed. Rheumatology has looked at the pathways, and they are unhappy. | JM to look at pathways being used in different local areas | JM to feedback at next HERPC | 9/17 |
| 2017.07.08 | Prescribing Guidelines, shared care frameworks for Approval | Apomorphine in Neurology- This now includes Domperidone, and information updated on ECG pre-treatment. | Approved | | 7/17 |
| | | Sublingual Immunotherapy (Grazax)- License change- now from 5 years. | Approved | | 7/17 |
| | | Riluzole for treatment of motor neurone disease- There is now a licensed liquid available. | JM to update re: crushing tablets. | SG to add to tracker | 9/17 |
| | | Preventing fatalities from medication loading doses: Guidance for Primary Care- No changes needed | Approved | | 7/17 |
| | | Guidelines for the Prescribing of Prasugrel – No changes- rarely used as only indicated for patients with allergy to Ticagrelor . | Approved | | 7/17 |
| | | Guidelines for the Prescribing of Ranolazine – An alert | Approved | | 7/17 |

| | | | | | | |
|------------|--|--|---|--|--|----------------------|
| | | card is to be given to patient on initiation of treatment, has been added. | | | | |
| 2017.07.09 | Primary Care Rebate Scheme – Standing Item | None | | | | |
| 2017.07.10 | Additional Minutes for Information | <ul style="list-style-type: none"> • a)MMIG (June) • b)HEY D&T (June) • c)HFT DTC (April) | Noted Noted Noted | | | 7/17 7/17 7/17 |
| 2017.07.11 | A.O.B | <p>JM shared with the group that the UTI section of the Antibiotic Guidelines now includes Nitrofurantoin 1st line, as Trimethoprim usage has been reduced. It was noted the sign after EGFR was the wrong way round. GH felt that out of hours GP's will be affected as they use Trimethoprim as 1st line. It was felt that more clarification was needed as to what 'low risk' meant.</p> <p>JS had received a report regarding Clozaril. This is a Red drug that was documented on a GP system for a patients repeat medications. The family looked up the drug on the internet, and this caused problems. It is possible to record a red drug on the GP system, for interaction purposes only.</p> | <p>JM to amend sign after EGFR. JM to email KM when the changes have been done for clarity. JM to also find out % of local figures from Labs</p> <p>JS to find out which GP this was.</p> | | | 7/17 |
| | | Next Meeting Wednesday 27 th September 2017, MR1/MR2 1.30 – 3.30 Health House, Willerby. | | | | |